Powered by HealthTechMovers.com
We added 2 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Seagen, SGEN
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
- Last Price: $176.77
- Price Change: -$3.34, -1.85%
- Yearly Gain: 14.52%
- Market Cap: $33.15B
- P/E Ratio: -47.717
Here are 3rd party ratings for SGEN:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 35% (87 out of 251)
What is the sentiment on the street regarding Seagen ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Positive
If you are interested in SGEN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on SGEN before you decide to make any investment.
Click here for chart >>
Altimmune, ALT
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Last Price: $12.2
- Price Change: $0.94, 8.35%
- Yearly Gain: 20.56%
- Market Cap: $486.65M
- P/E Ratio: -4.643
Here are 3rd party ratings for ALT:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 37% (93 out of 251)
What is the sentiment on the street regarding Altimmune ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Positive
If you are interested in ALT or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ALT before you decide to make any investment.
Click here for chart >>
Thanks for reading!
